AR056213A1 - Arilsulfonilcromanos como inhibidores de 5-ht6 - Google Patents

Arilsulfonilcromanos como inhibidores de 5-ht6

Info

Publication number
AR056213A1
AR056213A1 ARP060104782A ARP060104782A AR056213A1 AR 056213 A1 AR056213 A1 AR 056213A1 AR P060104782 A ARP060104782 A AR P060104782A AR P060104782 A ARP060104782 A AR P060104782A AR 056213 A1 AR056213 A1 AR 056213A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
aryl
cyano
optionally substituted
Prior art date
Application number
ARP060104782A
Other languages
English (en)
Inventor
Jacob Berger
Joan Marie Caroon
Francisco Javier Lopez-Tapia
Lee Edwin Lowrie Jr
Dov Nitzan
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37808173&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056213(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR056213A1 publication Critical patent/AR056213A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (1), o una sal farmacéuticamente aceptable, un isomero optico individual, una mezcla racémica o no racémica de los mismos, en la que m es un numero de 0 a 2, n es un numero de 1 a 3; p es un numero de 0 a 3; Ar es arilo opcionalmente substituido o heteroarilo opcionalmente substituido; X es -C(O)- o -CRaRb-, en el que Ra es hidrogeno o alquilo; y Rb es hidrogeno, alquilo C1-6 o hidroxi; R1 y R2 con independencia entre si son hidrogeno; alquilo C1-6; alcoxi C1-6-alquilo C1-6; hidroxi-alquilo C1-6; -CH2-C(O)-OCH3; -CH2-C(O)-NH-CH3; o ciano-alquilo C1-6; o uno de R1 y R2 es hidrogeno o alquilo C1-6 y el otro es un heteroarilo o heterociclilo de cinco o seis eslabones que contiene uno o dos átomos de nitrogeno y que está opcionalmente substituido por hidroxilo; ciano-alquilo C1-6; cicloalquilo C3-8; aril-alquilo C1-6; o -(CH2)r-Y-Rh, en el que Y es -C(O)- o -SO2-; r es el numero 0, 1 o 2; y Rh es alquilo C1-6; cicloalquilo C3-8; alcoxi C1-6; ciano-alquilo C1-6; halo-alquilo C1-6; hidroxi; amino; NH-alquilamino C1-6; N,N-di-alquilamino C1-6; hidroxi-alquilo C1-6 cuyo grupo hidroxi puede estar acetilado; arilo; aril-alquilo C1-6; o aril-alquiloxi C1-6-alquilo C1-6; o R1 y R2 junto con el átomo de nitrogeno al que están unidos pueden formar un anillo de tres a siete eslabones que contiene opcionalmente un heteroátomo adicional, elegido entre N, O y S y que está opcionalmente substituido por hidroxilo; o R1 y R2 junto con el átomo de nitrogeno al que están unidos pueden formar un grupo guanidinilo o un grupo amidinilo; R3 y R4 con independencia entre sí son hidrogeno o alquilo C1-6; o uno de R3 y R4 junto con uno de R1 y R2 y los átomos a los que están unidos pueden formar un anillo de cinco o seis eslabones; o R3 y R4 juntos pueden formar =NRc en el que Rc es hidrogeno o alquilo C1-6; y cada R5 con independencia de su aparicion es halogeno, alquilo C1-6, halo-alquilo C1-6, hetero-alquilo C1-6, ciano, -SO2Rd, -C(=O)- NReRf, -SRd, -C(=O)-Rg; en los que cada uno de Rd, Re y Rf con independencia de su aparicion es hidrogeno o alquilo C1-6; y Rg es hidrogeno, alquilo C1-6, hidroxi o alcoxi C1-6.
ARP060104782A 2005-11-03 2006-11-01 Arilsulfonilcromanos como inhibidores de 5-ht6 AR056213A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73294005P 2005-11-03 2005-11-03

Publications (1)

Publication Number Publication Date
AR056213A1 true AR056213A1 (es) 2007-09-26

Family

ID=37808173

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104782A AR056213A1 (es) 2005-11-03 2006-11-01 Arilsulfonilcromanos como inhibidores de 5-ht6

Country Status (19)

Country Link
US (1) US7754759B2 (es)
EP (1) EP2027104B1 (es)
JP (1) JP2009514828A (es)
KR (1) KR100984897B1 (es)
CN (1) CN101300246A (es)
AR (1) AR056213A1 (es)
AT (1) ATE499355T1 (es)
AU (1) AU2006310612A1 (es)
BR (1) BRPI0618206A2 (es)
CA (1) CA2628173A1 (es)
DE (1) DE602006020351D1 (es)
ES (1) ES2359735T3 (es)
IL (1) IL190868A0 (es)
NO (1) NO20081818L (es)
NZ (1) NZ567285A (es)
RU (1) RU2008115032A (es)
TW (1) TWI327914B (es)
WO (1) WO2007051735A1 (es)
ZA (1) ZA200803422B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354548B2 (en) * 2010-02-19 2013-01-15 Bristol-Myers Squibb Company Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase
CN113200952B (zh) * 2021-04-13 2023-03-10 江西师范大学 一种串联环化反应合成2-氨基-3,3-二氯代色满酮或2-氨基-3,3-二溴代色满酮的方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
IL109647A (en) * 1989-02-27 1997-04-15 Lilly Co Eli Intermediate compounds for ring-substituted 2-amino-1, 2, 3, 4-tetra- hydronaphthalenes and 3-aminochromanes
US5506192A (en) * 1990-06-07 1996-04-09 Sandoz Ltd. Substituted phthalides and heterocyclic phthalides
DE69128477T2 (de) * 1990-07-27 1998-07-16 Chugai Seiyaku K.K., Tokio/Tokyo Benzopyranderivat
US5401848A (en) 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
DE4102103A1 (de) 1991-01-25 1992-08-20 Bayer Ag Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5817693A (en) * 1991-11-05 1998-10-06 Cousins; Russell Donovan Endothelin receptor antagonists
ZA93436B (en) * 1992-01-24 1993-08-25 Chugai Pharmaceutical Co Ltd Benzopyran derivatives
ES2145129T3 (es) * 1992-08-17 2000-07-01 Chugai Pharmaceutical Co Ltd Derivados de benzopirano y benzoxazina.
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU684568B2 (en) 1994-01-31 1997-12-18 Pfizer Inc. Neuroprotective chroman compounds
US6150402A (en) * 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US5869478A (en) 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
CZ418597A3 (cs) 1995-06-30 1998-06-17 Pharmacia & Upjohn Company 1,6-disubstituované izochromany pro léčbu bolestí hlavy při migréně
US5663194A (en) * 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
DE69715865T2 (de) 1996-07-01 2003-08-07 Schering Corp., Kenilworth Muscarin-antagonisten
EP1019035A4 (en) * 1996-08-21 2001-10-17 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US6559144B2 (en) * 1997-02-13 2003-05-06 Merck Patent Gesellschaft Mit Bicyclic amino acids
ATE390404T1 (de) * 1997-02-27 2008-04-15 Takeda Pharmaceutical Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
TWI242011B (en) * 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
DE19754573A1 (de) * 1997-12-09 1999-06-10 Bayer Ag Pharmazeutische Zusammensetzung zur Behandlung von Schlaganfall und Schädel-Hirn-Trauma
ES2144355B1 (es) 1997-12-30 2001-01-01 Ferrer Int Compuestos derivados del cromeno.
FR2778662B1 (fr) * 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6586475B1 (en) * 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
KR100660788B1 (ko) * 1998-12-04 2007-02-28 다케다 야쿠힌 고교 가부시키가이샤 벤조푸란 유도체, 그 제조법 및 용도
CA2404736C (en) * 2000-04-03 2011-12-06 Takeda Chemical Industries, Ltd. Process for producing amine derivatives
EP1292310A1 (en) 2000-05-10 2003-03-19 SmithKline Beecham Corporation Novel anti-infectives
DE10044091A1 (de) * 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
AR035858A1 (es) * 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
EP1405312B1 (en) 2001-07-02 2008-02-06 Koninklijke Philips Electronics N.V. Waveform equalizer for obtaining a corrected signal and apparatus for reproducing information
WO2003011284A1 (en) * 2001-08-03 2003-02-13 Pharmacia & Upjohn Company 5-arylsulfonyl indoles having 5-ht6 receptor affinity
EP1432696A1 (en) * 2001-10-04 2004-06-30 Wyeth Chroman derivatives as 5-hydroxytryptamine-6 ligands
WO2003029239A1 (en) * 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
WO2003037262A2 (en) 2001-10-29 2003-05-08 Smithkline Beecham Corporation Novel anit-infectives
AU2003248566A1 (en) 2002-05-24 2003-12-12 Smithkline Beecham Corporation Novel anti-infectives
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
EP1513828A1 (en) 2002-06-20 2005-03-16 Biovitrum AB New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
US20040097492A1 (en) * 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
US7902203B2 (en) * 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
US20040162285A1 (en) * 2002-11-01 2004-08-19 Pratt John K. Anti-infective agents
WO2004052313A2 (en) 2002-12-11 2004-06-24 Smithkline Beecham Corporation Anti-infectives
AU2003300956A1 (en) 2002-12-11 2004-06-30 Smithkline Beecham Corporation Anti-infectives
AU2003297235A1 (en) 2002-12-17 2004-07-22 Smithkline Beecham Corporation Anti-infectives
WO2005019191A2 (en) 2003-08-25 2005-03-03 Abbott Laboratories 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20070208166A1 (en) 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
BRPI0510642A (pt) 2004-05-05 2007-11-20 Hoffmann La Roche arilsulfonil benzodioxanos úteis para modulação do receptor de 5-ht6, do receptor de 5ht2a ou ambos
US7378415B2 (en) * 2004-09-30 2008-05-27 Roche Palo Alto Llc Benzoxazine and quinoxaline derivatives and uses thereof
SI1831159T1 (sl) * 2004-12-21 2010-04-30 Hoffmann La Roche Derivati tetralina in indana ter njune uporabe

Also Published As

Publication number Publication date
IL190868A0 (en) 2008-11-03
CN101300246A (zh) 2008-11-05
DE602006020351D1 (en) 2011-04-07
WO2007051735A1 (en) 2007-05-10
ES2359735T3 (es) 2011-05-26
NO20081818L (no) 2008-06-19
US7754759B2 (en) 2010-07-13
RU2008115032A (ru) 2009-12-10
TW200800163A (en) 2008-01-01
KR100984897B1 (ko) 2010-10-01
EP2027104B1 (en) 2011-02-23
EP2027104A1 (en) 2009-02-25
ZA200803422B (en) 2009-09-30
JP2009514828A (ja) 2009-04-09
NZ567285A (en) 2010-06-25
AU2006310612A1 (en) 2007-05-10
KR20080074935A (ko) 2008-08-13
TWI327914B (en) 2010-08-01
CA2628173A1 (en) 2007-05-10
BRPI0618206A2 (pt) 2011-08-23
US20070099908A1 (en) 2007-05-03
ATE499355T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO5660261A2 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion de estos y usos de estos
CR8756A (es) Derivados de acido carboxilico bencimidazolona
AR086319A1 (es) Compuestos heterociclicos fusionados como moduladores de canal ionico
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
AR083070A1 (es) Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc
AR041661A1 (es) Compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos procesos para su preparacion y composiciones farmaceuticas que lo contienen
AR047974A1 (es) Derivados de alquilpiperazina y alquilhomopiperazina-carboxilatos, su preparacion y su aplicacion en terapeutica
ECSP099395A (es) Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
AR045901A1 (es) Glucocorticoesteroides especificos con actividades antiinflamatoria y antialergica,composiciones farmaceuticas que los contienen,y procedimientos para su preparacion,
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR069494A1 (es) Derivados de acidos fosfonicos
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR086590A1 (es) Compuestos de ciclohexanona y herbicidas que los comprenden
CO6020016A1 (es) Derivados de 1,2,4,5 tetrahidro-3h-benzapezinas su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
AR063576A1 (es) Arilsulfonil- pirrolidinas como inhibidores 5-ht6
CO4980859A1 (es) Arilpiperazinas que tienen actividad sobre el receptor 1a de la serotonina
NI200600279A (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparación y su utilización en terapéutica
AR053435A1 (es) Derivados de 5-amminoindol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un madicamento para el tratamiento de enfermedades asociadas a la modulacion de receptores h3.
AR082004A1 (es) Compuestos de fusion de piridina
BR0315800A (pt) Derivados de imidazopiridina, seu processo de preparação e as composições farmacêuticas que os contêm

Legal Events

Date Code Title Description
FB Suspension of granting procedure